Skip to Content
by Bill Snyder | Wednesday, Mar. 19, 2014, 8:00 AM
A compound discovered at Vanderbilt University Medical Center has shed light on the nature of proteinuric kidney disease, damage to the kidney filter barrier caused by chronic conditions including obesity, hypertension and diabetes.
Reporting in the December 2013 issue of the Journal of Clinical Investigation, researchers led by a group at Harvard Medical School identified the calcium-permeable channel TRPC5 as a mediator of filtration barrier injury, and found that blocking the channel with a small molecule can protect the kidney filter.
The inhibitory compound, ML204, was identified in 2011 using a cell-based high throughput fluorescence assay by a multi-center team co-led by Vanderbilt’s Corey Hopkins, Ph.D., and Craig Lindsley, Ph.D., who also participated in the current study.
A leaky filter barrier is a risk factor for cardiovascular disease, kidney failure and death. The use of ML204 in this study highlights the importance of highly selective small molecules to probe the physiological role of targets for potential new treatments, the researchers said.
The Vanderbilt contribution to the study was made possible by a National Institute of Health/Molecular Libraries Probe Production Centers Network grant, MH084659.
Send suggestions for articles to highlight in Aliquots and any other feedback about the column to email@example.com
Bill Snyder, (615) 322-4747
Health and Medicine, Reporter, Research Aliquots, Corey Hopkins, Craig Lindsley, Department of Chemistry, Department of Pharmacology, drug discovery, high throughput screening core, Journal of Clinical Investigation, kidney, kidney disease, medicinal chemistry, Reporter March 14 2014
There are lots of ways to keep up with Vanderbilt. Choose your preferred method: